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5-year survival rate in patients with early adenocarcinoma of the gastro-esophageal junction
or stomach (AGE/S) in Caucasian patients is reported to be 60–80%. We aimed to identify
prognostic markers for patients with UICC-I without lymph-node involvement (N0).
Methods
Clinical data and tissue specimen from patients with AGE/S stage UICC-I-N0, treated by
surgery only, were collected retrospectively. Tumor size, lymphatic vessel or vein invasion,
grading, classification systems (WHO, Lauren, Ming), expression of BAX, BCL-2, CDX2,
Cyclin E, E-cadherin, Ki-67, TP53, TP21, SHH, Survivin, HIF1A, TROP2 and mismatch
repair deficiency were analyzed using tissue microarrays and correlated with overall and
tumor related survival.
Results
129 patients (48 female) with a mean follow-up of 129.1 months were identified. 5-year over-
all survival was 83.9%, 5-year tumor related survival was 95.1%.
Poorly differentiated medullary cancer subtypes (p<0.001) and positive vein invasion
(p<0.001) were identified as risk factors for decreased overall—and tumor related survival.
Ki-67 (p = 0.012) and TP53 mutation (p = 0.044) were the only immunohistochemical mark-
ers associated with worse overall survival but did not reach significance for decreased
tumor related survival.
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Conclusion
In the presented study patients with AGE/S in stage UICC-I-N0 had a better prognosis as previ-
ously reported for Caucasian patients. Poorly differentiated medullary subtype was associated
with reduced survival and should be considered when studying prognosis in these patients.
Introduction
Adenocarcinoma of the esophago-gastric junction and stomach (AEG/S) is the fourth most
common cancer worldwide in men and the fifth most common cancer diagnosis in women
[1]. The prognosis of patients with AEG/S is poor, making it the second leading cause of cancer
death worldwide [1].
Complete resection (R0) is considered the treatment of choice with curative intent, yet, in
up to 40% of patients tumor recurrence occurs even after R0 resection [2]. An extended D2
lymphadenectomy as surgical procedure is well established, confirming the role of lymphatic
invasion in this cancer entity [3,4]. Approximately 30% of patients with AEG/S exhibit stage
UICC I at time of diagnosis [5] and despite early tumor-stage and radical tumor resection, this
group of patients has a 5-year overall survival rate of only 60%–80% [6,7]. In these studies
lymph node involvement was the main risk factor for tumor relapse. Due to higher incidence
of this cancer type in East Asia, most studies on prognosis and survival describe patients from
Japan and China. Solely Borie et al. [8] studied the survival of Caucasian patients stage UICC I
stratified according to lymph node involvement and demonstrated a tumor related five year
survival of 92% in patients without lymph node involvement.
In the search for additional and refined prognostic risk factors in advanced tumor stages,
several studies analyzed histomorphological criteria like tumor size, lymphatic vessel invasion,
vein invasion, grading, Lauren classification, WHO classification, and MING classification [9–
14]. Several studies described molecular markers considered predictive for survival of which
we selected for immunohistochemical evaluation and categorized in subgroups: markers for
proliferation (Ki-67 [15]), cell cycle regulation (Cyclin E [16–18], p21 [19], TP53 [20]), apopto-
sis (BAX [21], BCL [22], Survivin [23–25]), cell adhesion (E-cadherin [26–28]), cell differentia-
tion (CDX2) [29], SHH (Sonic hedgehog) [30], TROP2 [31], HIF1A (hypoxia induced factor
1α) [32] and mismatch repair deficiency [33].
These biomarkers have not yet been analyzed in this subgroup with AEG/S, UICC I without
the main confounder lymph node involvement in order to refine the identification of patients
at high-risk.
To this end we conducted this retrospective study with the aim to identify prognostic histo-
pathological and immunohistochemical markers using tissue microarrays (TMAs) from
patients with AEG/S stage UICC I-N0 and correlated these data with overall survival and
tumor related survival. Refined biomarkers in this subgroup might not only be predictive for
survival, but might guide treatment to improve survival in high-risk patients by possibly inten-
sifying treatment by adjuvant chemotherapy or chemoradiotherapy.
Material and Methods
Patients
Clinical data from patients with AEG/S stage pT1 and pT2 pN0M0, treated solely by surgery
between September 1993 and May 2010 at Charité—University Medicine Berlin, were collected
retrospectively.
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The data including patient characteristics and follow-up information were retrieved from
the patient management software (SAP1) and the regional population-based cancer registry
(Gemeinsames Krebsregister). This study was approved by the Institutional Ethical Review
Board of the Charité (EA4/115/10).
All procedures followed were in accordance with the ethical standards of the responsible
committee on human experimentation (institutional and national) and with the Helsinki Dec-
laration of 1964 and later versions. No patient consent was necessary since this was a retro-
spective study. Patients’ records were collected and anonymized, de-identified before the
analysis.
Patients without recurrent disease were followed-up for a minimum period of 24 months.
Overall survival, used as a measure of prognosis, was defined as time from diagnosis to death
or last follow-up. Tumor related survival was defined as time from diagnosis to tumor related
death or last follow-up.
Tissue Samples
Tissue samples were collected from the pathological archive of the Charité—University Medi-
cine Berlin. From 129 surgically treated patients 80 paraffin embedded tumor samples were
available. A specialist in gastrointestinal pathology (H.B.) reanalyzed and reconfirmed the pri-
mary postoperative histological diagnosis and tumor stage and classified the histological archi-
tecture of gastric carcinoma using Lauren’s, Ming and WHO classification [34]. According to
the WHO classification for colon and rectum carcinoma we added the subtype of medullary
tumors to our analysis [34–36]. We defined the poorly differentiated medullary cancer (PMC)
subtype in congruence with Adachi et al. as a tumor characterized by sheets of monomorphic
malignant cells showing solid growth and absence of glandular growth [35]. Tumor cells show
only little pleomorphism, have round to oval, large nuclei and a high nuclear to cytoplasmic
ratio, morphologically resembling medullary type colorectal cancer. The PMCs did not show a
deficiency of the mismatch repair system, as tested by immunohistochemistry.
Additional data concerning tumor size, depth of invasion, and tumor invasion of veins or
lymphatic vessels were extracted from the Charité—University Medicine patient management
software.
TMA and Immunohistochemistry
Tissue samples were screened in a HE-stained section for representative areas of solid tumors.
Two 1 mm-diameter tissue cores were punched out from each of the 80 available cases and
were transferred to a recipient paraffin block. Tissue from a tonsil was used as positive staining
control and was also transferred to the same paraffin block. After re-melting, sections (4 μm-
thick) were consecutively cut from each tissue microarray block. HE staining was performed
on TMA sections for confirmation of tumor and non-tumor tissue.
Immunohistochemical analysis was performed on TMA sections using monoclonal anti-
bodies. For pre-treatment a target retrieval solution (TRS) (HIF1A) or citrate buffer (pH = 6.0,
0.1M) was used. Antibody binding was visualized using an APAAP-Kit (K5000 Dako1) for E-
cadherin (1:50, clone 36B5, Novocastra1), Ki67 (1:200, Clone MIB-1, Dako1), BCL2 (1:25,
clone 124, Dako1), HIF1A (1:100, Clone Halpha111a, BioZol1); K5005 Dako1 for CDX2
(1:600, clone CDX2-88, Biogenex1), CD3 (1:100, clone LN10, Novocastra1) TP53 (1:100,
clone DO-7, Dako1), TP21 (1:10, clone DCS-60.2, Thermo Scientific1), BAX (1:500, Clone
A3533, Dako1, Cyclin E (1:100, clone HE12, Invitrogen1), Survivin (1:200, clone 12C4,
Dako1), SSH (1:500, clone EP1190Y, Dako1) and a biotin labeled anti-goat IgG Antibody
(Dako E0466) for TROP2 (1:100, clone P09758, R&D Systems1). For the mismatch-repair
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proteins immunohistochemistry was performed on an automated staining system (BenchMark
Ultra, Roche Ventana, Germany) using prediluted antibodies (all Roche Ventana) MLH1
(clone M1), PMS2 (clone EPR3947), MSH2 (clone G219-1129), and MSH6 (clone 44) follow-
ing the manufacturer’s instructions.
Membrane, cytoplasmatic and nuclear stained cells with E-Cadherin, BCL2, HIF1A, BAX,
SSH and solely nuclear stained cells with Cyclin E, TP21, CDX2 were scored according to the
intensity of staining (0, none to weak; 1 = weak; 2 = moderate; 3 = strong) and the percentage
of tumor cells stained (0 = 0% positive; 1 = 1–25% positive, 2 = 26–50% positive; 3 = 51–75%
positive and 4,> 75% positive). Tumor samples with a score higher than 3 were evaluated as
positive cases.
Concerning Ki-67, tumors with a proliferation rate higher than 20% were regarded as
highly proliferative tumors. For Survivin, all tumors with more than 5 percent positively
stained cell nuclei were scored as Survivin positive samples [37]. A high number (75–100%) of
TP53 positive stained cells with a strong nuclear staining intensity or tumors with no TP53
positive cells was used as a surrogate parameter for TP53 mutated samples [38,39].
Mismatch repair deficiency was scored, when a tumor showed specific loss of nuclear stain-
ing for at least one of the markers (MLH, PMS2, MSH2, MSH6)
The count of CD3 positive cells was performed in 4 representative regions of the tumor.
The average of counted cells was normalized in 0.1mm2 of tumor area.
Each core was blindly scored by two independent evaluators (C.T. and S. D.) and reviewed
by one pathologist (H.B.) and one biologist highly experienced in pathohistology (M.H.) and
reconciled after intensive discussion.
Statistics
Quantitative values are expressed as mean± standard deviation, median, and range, and cate-
gorical values with absolute and relative frequencies (count and percent). Overall survival was
evaluated in months from time of diagnosis until death or until the most recent follow-up
using the Kaplan–Meier plots. Differences in the survival curves were evaluated by the log-
rank test for significance. The X2-test was used for comparison of frequencies. A p-
value < 0.05 was considered as statistically significant. IBM SPSS Version 21 (Ehningen, Ger-
many) was used for statistical analysis.
Reporting recommendations for tumor marker prognostic studies (REMARK) were
applied for this study whenever applicable [40].
Results
Clinical Characteristics of Patients
Data of 129 patients (female = 48, age 29–90 years, median age 62.9 years) were retrieved for
this study (see Table 1). The cohort consisted of 96 patients with gastric cancer (2 pts. upper
third, 26 middle third, 55 lower third, 8 couplet stomach and 5 with no specified position in
the stomach) and 33 patients with carcinoma of the gastroesophageal junction. A D2 lymph
node dissection was performed in 97.6% (126 patients) of AEG and stomach resections (two
patients had only a D1 dissection and in one patient lymph node dissection status was not
reported.)
The mean follow-up was 129.1 months and 21 patients (16.3%) died during the follow-up
period, but only nine patients (7%) died from recurrence of AEG/S.
The 5-year overall survival of our population was 83.9%, the 5-year tumor related survival
was 95.1% (Fig 1). A relapse of AEG/S occurred in nine patients whereas 120 patients
remained relapse-free in the observation period.
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Table 1. Patient characteristics collected from the patient management software and the regional population-based cancer registry (n = 129).
Pts. (%) Tumor related Survival (%) Overall survival (%)
5-year 10-year Log Rank 5-year 10-year Log Rank
Sex
Female 48 (37.2%) 95.8 93.0 0.713 91.6 74.8 0.569
Male 81 (62.8%) 94.7 91.0 79.0 69.7
Tumor size
T1 88 (68.2%) 95.4 95.4 0.153 86.7 77.5 0.225
T2 41 (31.8%) 94.8 85.6 79.3 61.6
Tumor Location
AEG 33 (25.6%) 90.5 85.2 0.519 81.8 71.1 0.266
S 1/3 2 (1.6%) 100 100 50.0 50.0
S 2/3 26 (20.2%) 100 94.4 92.3 87.2
S 3/3 55 (42.6%) 94.3 92.6 87.1 75.5
S total 8 (6.2%) 100 100 100 100
Unspecified 5 (3.9%) - - - - - -
Lymphatic Vessel Invasion
L0 66 (51.2%) 93.5 88.3 0.369 78.4 65.1 0.971
L1 14 (10.9%) 80.0 80.0 75.0 60.0
Unspecified 49 (38.0%) - - - - - -
Vein Invasion
V0 63(48.8%) 96.7 91.3 0.005 85.9 71.3 0.165
V1 8 (6.2%) 60.0 60.0 42.9 42.9
Unspecified 58(45.0%) - - - - - -
Grading
G1 12 (9.3%) 100 100 0.495 100.0 83.3 0.937
G2 42 (32.6%) 92.7 86.5 82.1 65.4
G3 71 (55%) 95.5 93.5 80.9 70.9
G4 1 (0.8%) 100 100 0.0 0.0
Unspecified 3 (2.3%) - - - - - -
Resection
R0 98 (76.0%) 94.6 89.8 <0.001 82.2 68.0 0.001
R1 1 (0.8%) 0.0 0.0 0.0 0.0
Unspecified 30 (23.3%) - - - - - -
Lymph node Resection
D2 126 (97.6%) 94.7 91.7 0.758 88.7 78.3 0.473
D1 2 (1.6%) 100 100 50.0 50.0
Unspecified 1 (0.8%) - - - - - -
Lauren Classification
Intestinal 46 (35.7%) 93.3 90.5 0.533 82.0 64.0 0.721
Diffuse 36 (27.9%) 91.4 87.3 81.5 72.4
Mixed 11 (8.5%) 100 100 75.0 62.5
Unspecified 36 (27.9%) - - - - - -
Relapse
Yes 9 (7%) - - - 33.3 0.0 <0.0001
No 120 (93%) - - - 89.2 79.7
Total
129 (100%) 95.1 91.8 - 83.9 71.4 -
doi:10.1371/journal.pone.0168237.t001
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A stage pT1N0M0 was assigned to 68.2% of patients (88/129), and 31.8% of patients (41/129)
were pT2N0M0. In 80 cases the information of lymphatic vessel invasion was described and 14
(10.9%) were staged as L1 and 66 (51.2%) as L0. In 71 cases the vein invasion level was docu-
mented. Eight patients (6.2%) were staged as V1 and 63 (48.8%) as V0 (Table 1).
Histopathological Characteristics
From 129 patients with clinical data, 80 formalin-fixed paraffin embedded tissue samples were
available and reassessed (Table 2).
The reevaluation by a specialist in GI pathology (H.B.) resulted in 31 (38.8%) tumors staged
as T1a, 26 (32.5%) as T1b and 23 (28.8%) as T2. Seven (8.8%) tumors showed vein invasion
and 14 (17.5%) a lymphatic vessel invasion, while seven (8.8%) patients had G1, 27 (33.8%)
G2, and 46 (57.5%) G3 tumors.
The histopathological classification according to Lauren yielded 56 (70.0%) intestinal, 13
(16.3%) diffuse and 11 (13.8%) mixed type tumors. The WHO Classification resulted in: 40
(50.0%) tubular histology, 9 (11.3%) medullary, 3 (3.8%) papillary, 4 (5.0%) pyloric gland type,
2 (2.5%) mucinous, 15 (18.8%) signet ring and 7 (8.8%) mixed type tumors (medullar subtype
see Fig 2A and 2B). Using the Ming classification, tumors were in 38 cases (47.5%) of the
expansive and in 37 cases (46.3%) of the infiltrative type. In five cases (6.3%) a definite classifi-
cation was not possible (Table 2).
The correlation of histopathological characteristics with tumor related survival or overall
survival showed significant differences between the overall survival and tumor related survival
for the V0 and V1 subpopulation (5-year tumor related survival V0 96.7%, V1 60.0% p<0.001;
Fig 1. Kaplan–Meier estimates of tumor related survival measured from the date of first admission stratified by vein invasion status V0 (red) /V1
(blue) (left panel) and poorly differentiated medullary cancer (PMC) (blue) vs. other histopathological subtypes (no-PMC) (red) (right panel).
doi:10.1371/journal.pone.0168237.g001
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5-year overall survival V0 85.9%, V1 42.9% p = 0.001) (Table 2; Fig 1). Furthermore, we could
identify significant differences between poorly differentiated medullary cancer (PMC) sub-
types and non-PMC tumors (PMC vs. non-PMC: 5-year-overall survival 57.1% vs 87.8%;
p = 0.007, 5-year tumor related survival 75.0% vs 97.1%; p<0.001) (Fig 1). Tumor grading,
Lauren or Ming classification were no discriminating factors for survival (Table 2).
A multivariate cox regression model was not reasonable as the number of our cases, espe-
cially of relapsed cases, did not meet the critical number proposed by Peducci et al [41].
Immunohistochemistry
Although all cases were present in duplicate, between 12.5 to 20% (10–20) of the cases were
not usable for analysis in the TMA. Reasons for exclusion were cores with less than 10% tumor
tissue.
Table 2. Histopathological characteristics of the 80 tumor samples reevaluated from available formalin-fixed paraffin-embedded tissue samples.
PMC: Poorly differentiated medullary cancer.
Pts. (%) Tumor related Survival (%) Overall survival (%)
5-year 10-year Log Rank 5-year 10-year Log Rank
Tumor size
T1a 31 (38.8%) 93.4 93.4 0.952 88.9 88.9 0.179
T1b 26 (32.5%) 100.0 90.5 94.4 88.9
T2 23 (28.8%) 90.6 90.6 73.7 67.5
Vein Invasion
V0 73 (91.3%) 98.6 95.0 <0.001 92.1 85.9 0.001
V1 7 (8.8%) 53.6 53.6 42.9 42.9
Lymphatic Vessel Invasion
L0 66 (82.5%) 96.8 92.6 0.294 89.3 82.3 0.672
L1 14 (17.5%) 85.1 85.1 78.6 78.6
Grading
G1 7 (8.8%) 100 100 0.774 100 100 0.589
G2 27 (33.8%) 96.2 91.6 88.8 83.1
G3 46 (57.5%) 93.2 90.5 84.9 78.6
Lauren Classification
Intestinal 56 (70.0%) 92.6 88.0 0.280 86.2 80.7 0.282
Diffuse 13 (16.3%) 100 100 81.8 71.6
Mixed 11 (13.8%) 100 100 100 100
WHO Classification (modified)
Tubular 40(50.0%) 97.5 97.6 0.004 91.9 84.0 0.420
Papillary 3 (3.8%) 66.7 66.7 66.7 66.7
Mucinous 2 (2.5%) 100 100 50.0 -
PMC 9 (11.3%) 75.0 56.3 80.0 60.0
Pyloric gland type 4 (5.0%) 100 66.7 75.0 75.0
Poorly cohesive (signet ring) 15 (18.8%) 100 100 85.7 77.9
Mixed 7 (8.8%) 100 100 60 60
Ming Classification
Expansive 38 (47.5%) 91.7 88.3 0.175 86.3 82.7 0.903
Infiltrative 37 (46.3%) 97.4 97.4 88.4 80.8
Not possible 5 (6.3%) - - - - - -
Total
80 (100%) 94.8 91.4 - 83.9 71.4 -
doi:10.1371/journal.pone.0168237.t002
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In the analysis of the immunhistochemical markers BAX, BCL-2, CDX2, Cyclin E, E-Cad-
herin, Ki-67, TP53, TP21, SHH, Survivin, HIF1A, and TROP2 we could not find a significant
correlation with marker expression and prognosis (see Table 3.).
In a more detailed analysis for positive and negative markers we detected a lower 5-year
overall survival for Ki-67 high proliferative tumors (high: 79.9% vs. low: 100% p = 0.012) and
for tumors with TP53 surrogate mutation pattern (mut 66.3% vs. wt 92.5%; p = 0.044). These
markers showed a trend in the 5-year-tumor related survival analysis (Ki-67 high 90.2% vs.
Fig 2. Immunhistochemical and H&E staining of the TMA of gastric cancer specimens (200x). Poorly differentiated medullary cancer by H&E
staining (A) and CD3 staining (B). TP53 mutated (C) and wildtype (D) tumor sample.
doi:10.1371/journal.pone.0168237.g002
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Table 3. Immunohistochemical biomarker analysis: All immunohistochemical markers except Ki-67, TP53, and Survivin were analyzed using the
semiquantitative scoring system described in the method section.
Pts. (%) Tumor related survival (%) Overall survival (%)
5-year 10-year Log Rank 5-year 10-year Log Rank
BAX
Negative 15 (18.8%) 100 100 0.179 85.1 76.6 0.624
Positive 53 (66.3%) 92.0 86.9 83.6 72.8
Excluded 12 (15.0%) - - - - - -
BCL-2
Negative 53 (66.3%) 94.1 89.0 0.907 87.2 76.2 0.674
Positive 12 (15.0%) 91.7 91.7 83.3 83.3
n.a. 15 (18.8%) - - - - - -
CDX2
Negative 28 (35.0%) 89.1 84.9 0.506 84.1 75.2 0.742
Positive 37 (46.3%) 97.1 93.0 82.4 70.6
n.a. 14 (17.5%) - - - - - -
Cyclin E
Negative 34 (42.5%) 90.0 82.6 0.170 87.0 73.7 0.973
Positive 25 (31.3%) 95.7 95.7 83.3 77.8
n.a. 21 (26.3%) - - - - - -
E-Cadherin
Negative 13 (16.3%) 100 100 0.181 87.5 87.5 0.093
Positive 52 (65.0%) 91.7 86.2 78.8 67.9
n.a. 15 (18.8%) - - - - - -
HIF1A
Negative 62 (77.5%) 93.3 88.9 0.416 86.4 67.2 0.751
Positive 7 (8.8%) 100 100 85.7 68.6
n.a. 11 (13.8%) - - - - - -
Ki67*
Low proliferative 22 (27.5%) 100 100 0.075 100 100 0.012
High proliferative 42 (52.5%) 90.2 84.0 79.9 67.8
n.a. 16 (20.0%) - - - - - -
TP21
Negative 23 (28.8%) 95.7 95.7 0.275 85.9 79.7 0.453
Positive 37 (46.3%) 91.4 84.7 85.2 70.1
n.a. 20 (25.0%) - - - - - -
TP53**
Wt pattern 43 (53.8%) 97.7 94.7 0.057 92.5 80.2 0.044
Mutation pattern 23 (28.8%) 85.2 78.7 66.3 60.3
n.a. 14 (17.5%) - - - - - -
SHH
Negative 14 (17.5%) 100 100 0.220 90.9 77.9 0.493
Positive 56 (70.0%) 92.4 87.7 82.5 73.1
n.a. 10 (12.5%) - - - - - -
Survivin***
Negative 63 (78.8%) 93.4 89.3 0.560 86.2 77.2 0.390
Positive 3 (3.8%) 100 100 100 100
n.a. 14 (17.5%) - - - - - -
TROP2
(Continued )
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low 100% and TP53 mut: 85.2% vs wt 95.7%), but did not reach level of significance (Ki-67
p = 0.075 and TP53 p = 0.057).
The analysis of mismatch repair system deficiency and proficiency did not show any signifi-
cant differences for overall survival or tumor related survival (5-year tumor related survival
dMMR 100% vs. pMMR 92.1%, p = 0.461; 5-year overall survival dMMR 75.0% vs pMMR
82.0%, p = 0.842)
With regard to the above identified histomorphological risk factors (poorly differentiated
medullary cancer subtype, venous invasion) we found in PMC significantly more T2 tumors
(p = 0.034), more undifferentiated tumors (p = 0.024) and more p53 mutated tumors (p =
0.045). None of the PMC showed a deficient MMR.
For detailed classification of the PMC we counted the CD3 positive lymphocyte per
0.1mm2 tumor area. We detected less CD3 positive cells in the PMC compared to non-PMC
tumors (120.5 per 0.1mm2 vs 212.3 per 0.1mm2). The difference did not reach level of signifi-
cance (p = 0.1).
T2-stage was associated with positive venous invasion (p = 0.033) and p53 mutated subtype
(p = 0.003). Furthermore, we found a high correlation between V1 and L1 status (p>0.0001).
Discussion
The aim of this retrospective study was to identify prognostic histopathological and immuno-
histological markers for patients with AEG/S stage UICC I on top of the known main risk fac-
tor lymph node metastasis to identify potential high risk subgroups.
Detailed clinical data were retrieved for 129 patients and histopathological data were assess-
able in 80 cases in this study. This Caucasian UICCI/N0 patient cohort with FFPE samples is
one of the largest of gastric cancer in Europe as the incidence is substantial lower and tumor
stages are more advanced in comparison to Eastern Asia [42,43].
From 129 patients followed over 10 years we found 9 patients with tumor related death.
This high 5-year tumor-related overall survival of 95.1% proves the effectivity of surgical treat-
ment in this early stage disease without lymph node involvement. Similar favorable data are
well known from Asian patients (97.8% 5-year tumor-related overall survival) [44]. Similar
results in Caucasians were reported in a single study by Borie et al. with a 92% 5-year tumor-
Table 3. (Continued)
Pts. (%) Tumor related survival (%) Overall survival (%)
5-year 10-year Log Rank 5-year 10-year Log Rank
Negative 5 (6.3%) 100.0 100.0 0.466 100.0 50.0 0.837
Positive 63 (78.8%) 93.3 89.0 82.8 74.8
n.a. 12 (15.0%) - - - - - -
Mismatch repair system
Proficient 53 (66.3%) 92.1 87.3 0.461 82.0 72.0 0.842
Deficient 5 (6.3%) 100 100 75.0 75.0
n.a. 22 (27.5%) - - - - - -
Total
80 (100%) 94.8 91.4 - 83.9 71.4 -
*Ki-67: Samples > 20% positive cells were evaluated as high proliferative tumors.
** TP53 Samples with 75–100% stained cells and strong nuclear staining intensity were scored as TP53 mutated.
***Survivin: tumors with >5% positive stained nuclei were scored as positive.
n.a.: not assessable
doi:10.1371/journal.pone.0168237.t003
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related overall survival [8]. The large German gastric cancer trial showed in about 250 patients
recruited from 1986–1989 a 5-year overall survival depending on the number of resected
lymph nodes from 81%-85% in T1N0 stages to 67% in T2N0 stages [6]. These differences in
survival are probably attributable to increased surgical quality in the last decades and the
decreased postoperative 30 day mortality rate (mean 30 day mortality rate of 0.8% in 18 trials
between 1998–2014 [45] compared to the German gastric cancer trial with 5.2% [3]).
For the histopathological markers in our study, venous infiltration was a significant predic-
tor for tumor related death in our patient group (5 year-tumor related survival V0 96.7%, V1
60.0% p = 0.005). While these data are in accordance with Asian studies [10,11], we found a
higher number of patients with poorly differentiated medullary cancer subtype, namely 11.3%
(9/80) whereas the Asian data reported about 3.0% of PMC histology, defined as low differenti-
ated lymphoepithelioma-like tumor type with a small amount of stromal tissue [35,36].
Although definition of medullary subtype is still a point of discussion, our defining criteria are
easily reproducible. Similar to Asian patients, PMC subtype was associated with relapse and
reduced prognosis in our patient population [35,36]. Although PMC phenotype (see Fig 2A
and 2B) is not part of the classification systems currently in use (WHO, Ming, Lauren), it
seems to represent an atypical form of gastric cancer which should be studied further, consid-
ered as a separate entity, and included in histopathological classification systems [46].
According to our data, all other parameters analyzed, like Lauren and Ming classification,
tumor size, grading, lymph vessel invasion, and signet ring cell type, did not show a prognostic
relevance. As other authors found grading, lymph vessel invasion and tumor size as prognostic
in early tumor stages mainly with lymph node involvement [10–14], employing a more
detailed analysis (N0 versus N+) of the tumor, might explain these differences.
The conclusion from our immunohistochemical data for prognostic biomarkers is some-
what limited by the rather small number of cases, solely 58–70 from 129 included patients
could be analyzed, and the number of patients with tumor related death among this group
amounts to six patients (see Table 3.). A reduced overall survival for TP53 surrogate mutation
pattern and for high proliferative (Ki-67>20%) tumors could be demonstrated. The identified
histopathological risk factors vein invasion and PMC subtype were positively correlated with a
TP53 mutation pattern. TP53 and Ki-67 did not reach the level of significance in correlation
with disease relapse in contrast to correlation with death by any cause.
Yet, the results for TP53-mutating pattern and high proliferating tumors are in concor-
dance with other studies. Over all stages of gastric cancer Ki-67 is associated with metastasis
and disease progression in gastric cancer and is especially associated with lymph node involve-
ment in early diseases [47,48].
Also TP53 mutation is known to be associated with reduced survival [15,49,50] and the
mutation of TP53 plays a crucial role in the progression from intestinal metaplasia to gastric
cancer [49,51]. Despite missing significance (p = 0.057) for this biomarker, the immunohisto-
chemical TP53 surrogate mutation pattern seems to be a suitable molecular biomarker for
early gastric cancer.
This retrospective study in a non-selected group of patients with early adenocarcinoma of
the esophago-gastric junction and stomach corroborates older findings of a favorable progno-
sis in cases without lymph node involvement. We could confirm the negative prognostic role
of vein invasion in our population despite the small number of patients with relapse. Further-
more, we could identify the subtype of poorly differentiated medullary cancer as a risk factor
for disease recurrence in a Caucasian population.
The prognostic role of these findings has to be investigated in more detail in further ade-
quately powered prospective studies.
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